

**SAVE
THE DATE**

sanofi

• Simposio Sanofi •

Más allá de la piel en la dermatitis atópica

Chairman



Dra. Valeria Angles

Dermatóloga y Pediatra
Jefa de la Unidad de Dermatología infanto juvenil.
Hospital Italiano de Buenos Aires

Speakers



Dr. Claudio Parisi

Pediatra y Alergista
Jefe de la unidad de Alergia e Inmunología
Hospital Italiano de Buenos Aires, Argentina.



Dra. Mónica Novoa

Dermatóloga Pediátrica.
Fundación Santa Fé de Bogotá.
Centro Dermatológico
Federico Lleras Acosta. Colombia

Entrevistador



Dr. Guillermo Capuya

Médico diplomado en Comunicación Médica Científica



Martes 8 de abril

12:30 a 14:00 hs.



**Centro de Exposiciones y
Convenciones de Buenos Aires
Salones D&E**

Av. Figueroa Alcorta 2099, CABA

sanofi

INFORMACIÓN DESTINADA A LOS PROFESIONALES FACULTADOS PARA PRESCRIBIR O DISPENSAR MEDICAMENTOS.
Mayor información disponible a petición. Sanofi-Aventis Argentina S.A. – Tucumán 1, Piso 4º, C1049AAA, Ciudad Autónoma de Buenos Aires, Argentina. Tel: (011) 4732-5000 www.sanofi.com.ar



Información
del producto

Join our expert speakers for the upcoming ADVENT symposium as they discuss disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.

How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis

LEARN MORE

Thursday, April 10, 2025

12:30 PM–2:00 PM ART
Lunch will be provided

15th World Congress of Pediatric Dermatology (WCPD) in Buenos Aires

Centro de Convenciones de la Ciudad de Buenos Aires

ADD TO CALENDAR

Faculty



Amy Paller, MD, MS
Northwestern University
Feinberg School of Medicine
Chicago, IL, USA



Eulàlia Baselga, MD, PhD
Sant Joan de Déu Barcelona
Children's Hospital
Barcelona, Spain



Paula Luna, MD
Hospital Aleman
Buenos Aires, Argentina

Agenda

Welcome, Introductions, Objectives

Amy Paller

On the Surface: Restoring the Skin Barrier in Patients With AD

Amy Paller

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Eulàlia Baselga

Charting the Future: Preventing the Atopic March

Paula Luna

Summary and Conclusions

Amy Paller

sanofi | REGENERON®

ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron.
© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2501093 – 2.0 – 03/2025

Dupilumab is licensed for moderate-to-severe AD in patients 6 months and older in the USA. Dupilumab is licensed in patients from 6 months up to 11 years of age with severe AD in the EU, and patients 12 years and older with moderate-to-severe AD. Dupilumab is licensed for moderate-to-severe AD in patients 6 months to 5 years and patients 12 years and older, and in patients with severe AD from 6 years to 11 years in Argentina. Registration conditions differ internationally. Before prescribing the product, always refer to the prescribing information available in your country as Sanofi-Regeneron does not recommend the use of its products in any manner inconsistent with that described in the local full prescribing information.